Inventiva

Intercept Pharmaceuticals

This company develops and commercialises small molecule therapeutics to treat chronic liver diseases for healthcare providers and patients.

Metabolys

This biopharmaceutical company develops oral small molecules to treat metabolic diseases, specifically non-alcoholic steatohepatitis and type 2 diabetes, for the global healthcare market.

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

AKRO

This company develops injectable medicines to treat patients with serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis.

Eternygen

This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.

Cymabay Therapeutics

This biopharmaceutical company develops oral therapies for patients with chronic liver diseases and metabolic disorders including primary biliary cholangitis.

Rivus Pharmaceuticals

The company develops oral small-molecule medicines for patients with obesity and associated cardiometabolic diseases including heart failure and type 2 diabetes.

Resalis Therapeutics

This company develops non-coding RNA therapies to treat metabolic disorders, including obesity and fatty liver disease, for patients with unmet medical needs.